Effect of Peripheral μ-, δ-, and κ-Opioid Ligands on the Development of Tolerance to Ethanol-Induced Analgesia

Involvement of Peripheral Opioid Receptors in the Realization of Food Motivation Into Eating Behavior

The involvement of peripheral opioid receptors in the mechanisms of eating behavior is still unclear. The aim of this work was to study the role of peripheral, predominantly gastric mu and delta opioid receptors in the realization of food motivation in conditions of different energy costs for eating behavior. Experiments were performed under a between-sessions progressive ratio schedule of reinforcement in food-deprived rats. The level of food motivation was calculated using a self-developed method. Food intake, motor activity, and metabolic rate were recorded in fed and hungry animals. Results showed that intragastric administration of the mu opioid receptor agonist DAMGO led to an increase in the level of food motivation in the light variant of operant feeding behaviors. Food consumption did not change. At high costs for feeding behavior, the administration of DAMGO did not alter food motivation; however, food consumption and motor activity were reduced. Intragastric administration of the delta opioid receptor agonist DADLE did not lead to changes in the level of food motivation and physical activity, but inhibition of feeding behavior was observed in all reinforcement schedules. Three regulatory pathways of eating behavior in difficult food conditions by peripheral, predominantly gastric opioid receptors are hypothesized: environmental-inhibitory afferentations and suppression of the realization of food motivation into behavior; homeostatic-inhibitory action on food motivation; and rewarding-suppression of the anticipatory reinforcement.

Endogenous opiates and behavior: 2017

This paper is the fortieth consecutive installment of the annual anthological review of research concerning the endogenous opioid system, summarizing articles published during 2017 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides and receptors as well as effects of opioid/opiate agonists and antagonists. The review is subdivided into the following specific topics: molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors (1), the roles of these opioid peptides and receptors in pain and analgesia in animals (2) and humans (3), opioid-sensitive and opioid-insensitive effects of nonopioid analgesics (4), opioid peptide and receptor involvement in tolerance and dependence (5), stress and social status (6), learning and memory (7), eating and drinking (8), drug abuse and alcohol (9), sexual activity and hormones, pregnancy, development and endocrinology (10), mental illness and mood (11), seizures and neurologic disorders (12), electrical-related activity and neurophysiology (13), general activity and locomotion (14), gastrointestinal, renal and hepatic functions (15), cardiovascular responses (16), respiration and thermoregulation (17), and immunological responses (18).

Physiology and Pharmacology of Positive Reinforcement

An original concept of a two-stage mechanism of positive reinforcement is proposed. The first stage, "virtual" reinforcement, is formed in parallel with the action result acceptor when the result is still not achieved. At this stage, the importance of the planned result and the probability of its achievement are assessed. The greater are these indices, the stronger is "virtual" reinforcement. Hypothetically, the "virtual" reinforcement is mediated by dopamine release from nerve terminals in the mesencephalon. The "real" reinforcement (the second stage) occurs after achievement of the result. Probably, an important role in the mechanisms of the "real" reinforcement is given to endogenous opioids, cannabinoids, and GABA. Based on the advanced hypothesis on interaction between the central and peripheral subdivisions of the corresponding neurochemical systems, the review focuses on possibility of pharmacological intervention into the mechanisms of positive reinforcement by modifying activity of the peripheral opioid and dopamine receptors with the ligands that cannot cross blood-brain barrier.